Logotipo del repositorio
  • Facultades
  • Explorar Repositorio
    • Autores
    • Título
    • Materias
    • Fecha de publicación
  • Guías de ayuda
    • Sobre el repositorio
    • Guía de autoarchivo
    • Preguntas frecuentes
    • English
    • Español
    • Iniciar sesión
      ¿Nuevo Usuario? Pulse aquí para registrarse¿Has olvidado tu contraseña?
    1. Inicio
    2. Buscar por autor

    Examinando por Autor "Campos Valdes, Javiera"

    Mostrando 1 - 1 de 1
    Resultados por página
    Opciones de ordenación
    • Cargando...
      Miniatura
      Ítem
      Effectiveness of duloxetine versus other therapeutic modalities in patients with diabetic neuropathic pain: a systematic review and meta-analysis
      (MDPI, 2024-06-05) Valenzuela Fuenzalida, Juan José; López Chaparro, Michelle; Barahona Vásquez, Marisol; Campos Valdes, Javiera; Cordero Gonzalez, Javiera; Nova Baeza, Pablo; Orellana-Donoso, Mathias; Suazo Santibañez, Alejandra; Oyanedel Amaro, Gustavo; Gutiérrez Espinoza, Héctor
      Objectives: Diabetic peripheral neuropathy (DPN) is a chronic complication of diabetes mellitus (DM) with symptoms like intense pain and impaired quality of life. This condition has no treatment; instead, the pain is managed with various antidepressants, including duloxetine. The aim of this study is to analyze the evidence on the efficacy of duloxetine in the management of DPN. Methods: A systematic search in different databases was conducted using the keywords "diabetic neuropathy", "duloxetine therapy", "neuropathic pain", and "Diabetes Mellitus". Finally, eight studies were included in this meta-analysis. Results: All articles comparing duloxetine at different doses vs. a placebo reported significant differences in favor of duloxetine on pain scales like 24 h Average Pain Severity (standardized mean difference [SMD] = -1.06, confidence interval [CI] = -1.09 to -1.03, and p < 0.00001) and BPI Severity (SMD = -0.70, CI = -0.72 to -0.68, and p < 0.00001), among others. A total of 75% of the meta-analyses of studies comparing duloxetine at different doses showed a tendency in favor of the 120 mg/d dose. There were significant differences in favor of duloxetine when compared to routine care on the Euro Quality of Life (SMD = -0.04, CI = -0.04 to -0.03, and p < 0.00001) and SF-36 Survey (SMD = -5.86, CI = -6.28 to -5.44, and p < 0.00001) scales. There were no significant differences on the visual analog scale (VAS) when comparing duloxetine and gabapentin. Conclusions: Duloxetine appears to be effective in the management of DPN in different pain, symptom improvement, and quality of life scales.
    facebookinstagramtwitterYoutubelinkedin

    La Universidad

    • Normativa Institucional
    • Modelo Formativo
    • Planificación Estratégica
    • Transparencia
    • Acreditación
    • Imagen Corporativa

    Unidades

    • Vinculación con el Medio
    • Investigación
    • Internacional
    • Desarrollo y Relaciones Institucionales

    Servicios

    • Matrícula
    • Financiamiento
    • Biblioteca
    • Pago Online
    • Certificados en línea
    • Bolsa de trabajo Alumni

    Programas

    • Carreras Diurnas
    • Carreras Vespertinas
    • Cursos
    • Diplomados
    • Magíster
    • Especialidades

    Contáctanos

    • Avda. Pedro de Valdivia 1509
      Providencia, Santiago
    • Código Postal: 7501015
    • +56 2 24207100